Home

BIO President Jim Greenwood Asks NYSE to Reconsider Decision on Life Sciences Research

September 14, 2005
  • Contact: Contact Lisa Dry
    202-962-9231 Direct
    202-345-3673 Mobile
  • Recommend
  • Tweet
  • Print
  • Email

WASHINGTON, D.C. (September 14, 2005) -- On September 7, the New York Stock Exchange (NYSE) postponed the listing of Life Sciences Research (Huntingdon Life Science) in an apparent reaction to threats from animal rights terrorists. This week Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood issued a letter to John Thain, NYSE Chairman, and Catherine Kinney, NYSE President, asking them to reconsider their decision. A pdf of that letter is attached and can be viewed on BIO’s Web site at: http://www.bio.org/news/features/JGreenwood-NYSE.pdf

Key points include:

  • BIO is disappointed in this reaction to threats from terrorists

  • The postponement of the listing suggests biomedical research has taken a backseat to pressure tactics from extremists

  • Ethical animal research has been vital to virtually every major medical advance of the last century

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products.

###

About BIO
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling “innovations transforming our world.” Subscribe to BIOtechNOW.